Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Jan 19.
Published in final edited form as: Chemphyschem. 2021 Dec 9;23(2):e202100839. doi: 10.1002/cphc.202100839

Order-Unity 13C Nuclear Polarization of [1-13C]Pyruvate in Seconds and the Interplay of Water and SABRE Enhancement

Isaiah Adelabu a, Patrick TomHon b, Mohammad S H Kabir a, Shiraz Nantogma a, Mustapha Abdulmojeed b, Iuliia Mandzhieva b, Jessica Ettedgui c, Rolf E Swenson c, Murali C Krishna d, Thomas Theis b, Boyd M Goodson e, Eduard Y Chekmenev a,f
PMCID: PMC8770613  NIHMSID: NIHMS1762426  PMID: 34813142

Abstract

Signal Amplification By Reversible Exchange in SHield Enabled Alignment Transfer (SABRE-SHEATH) is investigated to achieve rapid hyperpolarization of 13C1 spins of [1-13C]pyruvate, using parahydrogen as the source of nuclear spin order. Pyruvate exchange with an iridium polarization transfer complex can be modulated via a sensitive interplay between temperature and co-ligation of DMSO and H2O. Order-unity 13C (>50%) polarization of catalyst-bound [1-13C]pyruvate is achieved in less than 30 s by restricting the chemical exchange of [1-13C]pyruvate at lower temperatures. On the catalyst bound pyruvate, 39% polarization are measured using 1.4 T NMR spectrometer, and extrapolated to >50% at the end of build-up in situ. The highest measured polarization of a 30-mM pyruvate sample, including free and bound pyruvate is 13% when using 20 mM DMSO and 0.5 M water in CD3OD. Efficient 13C polarization is also enabled by favorable relaxation dynamics in sub-microtesla magnetic fields, as indicated by fast polarization buildup rates compared to the T1 spin-relaxation rates (e.g., ~0.2 s−1 versus ~0.1 s−1, respectively, for a 6 mM catalyst-[1-13C]pyruvate sample). Finally, the catalyst-bound hyperpolarized [1-13C]pyruvate can be released rapidly by cycling the temperature and/or by optimizing the amount of water, paving the way to future biomedical applications of hyperpolarized [1-13C]pyruvate produced via comparatively fast and simple SABRE-SHEATH-based approaches.

Keywords: hyperpolarization, NMR, parahydrogen, 13C, pyruvate

Graphical Abstract

graphic file with name nihms-1762426-f0001.jpg

Order unity 13C polarization for [1-13C]pyruvate was demonstrated for catalyst-bound species by SABRE-SHEATH, which becomes possible due to favorable 13C relaxation dynamics in a microtesla magnetic field. The magnetic field, temperature and co-solvents heavily modulate the attainable 13C polarization, providing an opportunity for optimization to deliver highly polarized [1-13C]pyruvate quickly and cheaply for biomedical and other applications.

Introduction

NMR hyperpolarization techniques transiently boost nuclear spin polarization (P) by several orders of magnitude.[1, 2] The enhanced P can be stored on relatively long-lived 13C carriers of hyperpolarization, allowing them to be used as metabolic contrast agents with 4-6 orders of magnitude gain in NMR signal.[3, 4]

[1-13C]pyruvate is the leading hyperpolarized (HP) contrast agent.[5] It is currently under investigation in 14 clinical trials[5] for spectroscopic imaging of aberrant metabolism of cancer[4] and other diseases.[6] Such real-time metabolic studies[7] became possible due to the pioneering work of Ardenkjaer-Larsen and co-workers who established dissolution Dynamic Nuclear Polarization (d-DNP) technology (ca. 2003).[8] Despite major success in the research domain,[9] the production of HP [1-13C]pyruvate via d-DNP is slow (tens of minutes or longer) and expensive ($2M+ for a clinical device), representing a substantial barrier for clinical translation of this otherwise revolutionary contrast agent and molecular imaging modality. Metabolic MR scan with HP [1-13C]pyruvate takes less than a minute and uses no ionizing radiation.[7] This is in sharp contrast to clinical [18F]fluorodeoxyglucose Positron Emission Tomography scan requiring ~2 hours and exposing subjects to 30-50 mSv radiation.

More efficient and cost-effective approaches for production of HP [1-13C]pyruvate are needed to enable its widespread clinical use. One recent development is the use of the Parahydrogen Induced Polarization (PHIP)[10] technique by Reineri and co-workers, who pioneered the Side Arm Hydrogenation (SAH) variant of PHIP for production of HP [1-13C]pyruvate via SAH followed by magnetic field cycling (MFC) and de-esterification.[11] Indeed, P13C of up to 10% has been demonstrated for HP [1-13C]pyruvate using this approach[12] for in vivo validation studies.[13] The key limitation of this approach is the requirement for synthesis of unsaturated PHIP precursors.

Signal Amplification by Reversible Exchange (SABRE)[14] is a PHIP variant that requires no hydrogenation—instead, SABRE relies on reversible exchange of parahydrogen (p-H2) and the to-be-hyperpolarized substrate with a catalyst. Recently, after some success with indirect methods,[15] Duckett and co-workers[16, 17] and Goodson and co-workers[18] independently demonstrated that SABRE can be employed for direct hyperpolarization of 13C carboxylate moieties—including [1-13C]pyruvate (P13C~1.85%).[16] [1-13C]pyruvate forms a complex with the standard catalyst used for SABRE, [IrCl(COD)(IMes)] (IMes = 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene; COD = cyclooctadiene)],[19, 20] Scheme 1). The efficient hyperpolarization transfer from p-H2-derived hydrides to the 13C nuclear spins of [1-13C]pyruvate becomes possible by performing SABRE in sub-microtesla magnetic fields using SABRE in SHield Enables Alignment Transfer to Heteronuclei (SABRE-SHEATH).[21, 22] In this technique, the use of microtesla magnetic fields during enables spontaneous polarization transfer from p-H2-derived hydrides directly to the heteronucleus (i.e., anything else but protons) of to-be-hyperpolarized exchangeable substrate molecule, including 13C as shown in Figure 1a.[21-23]

Scheme 1.

Scheme 1.

Formation of [IrCl(H)2(DMSO)2(IMes)] (2) and [Ir(H)22-[1-13C]pyruvate)(DMSO)(IMes)] (3) complexes following activation of [IrIMes(COD)Cl] (1) pre-catalyst. Complex 1 was synthesized previously[24] according to Cowley and co-workers.[19] The complexes 1, 2, 3a and 3b are as indicated by Duckett and co-workers.[16]

Figure 1.

Figure 1.

a) Chemistry of SABRE-SHEATH hyperpolarization exchange of dominant complexes 3a and 3b and corresponding 13C NMR spectrum from the HP composition (30 mM [1-13C]pyruvate, 20 mM DMSO, 6 mM pre-catalyst): the sample was hyperpolarized at 0 °C and transferred to a 1.4 T NMR spectrometer for detection in ~5 seconds. Note the appearance of the residual free HP [1-13C]pyruvate signal (most down-field resonance) originating from sample warm-up during sample transfer; faster transfer following SABRE under these conditions yields spectra that are more dominated by the bound 3b resonance (inset; see Figure 3 for more details). b) Corresponding thermal reference spectrum from neat [1-13C]acetic acid. c) Diagram of the gas manifold and key components within the PHIP hyperpolarizer experimental design to be described elsewhere.

In even more recent work describing low-cost 50% p-H2 generators, we explored temperature dependence of SABRE-SHEATH polarization of pyruvate yielding 13C polarization of 1.2%.[25]

Results and Discussion

Here, we demonstrate that SABRE-SHEATH can produce order-unity 13C polarization in [1-13C]pyruvate in seconds, Figure 1a. Figure 1a shows a spectrum of 6 mM Ir-[1-13C]pyruvate complex composed of both 3a and 3b with P13C of 39% at the time of detection; a corresponding 13C reference spectrum from thermally polarized neat [1-13C]acetic acid is shown in Figure 1b. Most the 13C NMR measurements reported here were performed at the clinically relevant magnetic field of 1.4 T. Because the HP sample depolarizes during the 3-5-second long sample transfer (due to sample exposure in the Earth’s field and the 1.4 T field of the NMR spectrometer, see Supporting Information (SI) for details), the P13C value at the time of production (i.e., at the moment of completion of the SABRE-SHEATH process) is estimated to be >50%. This polarization value represents a conservative estimate, because 3b is not the only complex present as seen from high-resolution 1H NMR spectra of the hydride region (Figure S2), and our polarization calculations were based on the pre-catalyst 1 concentration, see SI. Therefore, we conclude that P13C can approach order-unity values under ideal conditions of 13C SABRE-SHEATH polarization build-up. We note that here, we are focused on the ultimate limit of achievable 13C polarization, instead of bulk production of HP [1-13C]pyruvate.

By decreasing the temperature of 13C SABRE-SHEATH to 0 °C, where maximum P13C is achieved, exchange is too slow to enable the appreciable 13C polarization build-up on the free species, Figure 1a. Only minute amounts of “free” HP [1-13C]pyruvate resonance (Figure 1a) is created during the ~3-5-second-long sample transfer from the shield (at 0 °C) to the bore of the 1.4 T NMR spectrometer (32 °C). The 3-5-second transfer period represents an experimental limitation required for reproducible detection of the NMR signal — indeed, in certain cases when faster transfer was used to reduce sample warm up, (inset of Figure 1a), the “free” HP pyruvate resonance is negligible. Therefore, we attribute virtually all of the detected HP pool to the catalyst-bound complexes 3a and 3b. The successive p-H2 exchanges with 3b result in accumulating polarization of the complex.

Kinetically, the build-up to these high P13C levels becomes possible because the 13C T1 relaxation time of HP [1-13C]pyruvate in this complex at 0.30 μT is long: 9.5 s (i.e., the spin relaxation rate is ~0.1 s−1) even at the relatively large catalyst concentration of 6 mM. In comparison, the 15N T1 of HP [15N]pyridine is less than 2 s at 6 mM catalyst concentration.[23] We rationalize these more favorable 13C relaxation dynamics in terms of the overall greater separation distance of the target 13C nucleus from the quadrupolar iridium catalyst center: i.e., the Ir-O-13C moiety versus the substantially shorter total bond distance (and by extension greater iridium-complex-mediated depolarization[26]) with an Ir-15N moiety. As a result, the effective 13C polarization build-up constant, Tb = 4.9 s, corresponds to an effective build-up rate of ~0.2 s−1—substantially faster (e.g., Figure 2c) than the corresponding spin relaxation rate (Figure 2d), allowing one to achieve order-unity 13C polarization.

Figure 2.

Figure 2.

Total 13C polarization of 13C-1 (i.e., integrating over all bound and free resonances) in 30 mM [1-13C]pyruvate (pyruvate to DMSO ratio of 30:20) as a function of magnetic transfer field (a), temperature (b), p-H2 bubbling duration (c), and in-shield decay (d). All experiments were performed at 7.7 atm of p-H2 pressure at 70 sccm p-H2 flow rate. Detailed mapping of other experimental parameters can be found in the SI. The data points marked with asterisks correspond to the cases when virtually all 13C HP signal originates from bound species 3a and 3b.

The reported SABRE-SHEATH experiments were performed using p-H2 bubbling through the solution (Figure 1c), which can be quickly and conveniently interrupted and restarted at will—thereby allowing one to quickly map the experimental parameter space in a systematic manner, in addition to the studies of relaxation dynamics discussed above. Careful optimization of the magnetic field and temperature of 13C SABRE-SHEATH for [1-13C]pyruvate (Figures 2a,2b respectively) revealed the optimum polarization transfer field BT of ~ 0.3 μT and the optimum polarization transfer temperature TT of ~0 °C (P13C values in Figure 2 were computed for total 13C polarization of 30 mM [1-13C]pyruvate to provide a fair comparison of the entire hyperpolarization pool, regardless of its origin: free, 3a, or 3b species).

Temperature has a profound effect on the exchange rates of [1-13C]pyruvate on complex 3b—Figure 3a shows a variable temperature SABRE-SHEATH experiment with monotonic disappearance of free HP resonance at lowered temperatures, because the ultra-slow exchange rate does not allow any appreciable release of HP species from complex 3b into the free state. When SABRE-SHEATH is performed at elevated temperatures (e.g., 22 °C, Figure 3a), [1-13C]pyruvate exchange with the polarization transfer complex is accelerated, leading to hyperpolarization of both free and bound 3b species in the expected pyruvate:pre-catalyst (~5:1) ratio. Even though the 13C polarization was nearly fully locked in the bound 3b state at 0 °C (Figure 3b, blue trace), the 13C polarization bolus can be rapidly released if the NMR tube containing the HP solution is rapidly warmed up after sample transfer from the shield, but before inserting the sample in the NMR detector. The effect of rapid release of HP pyruvate from 3b can potentially enable a wide range of new strategies to improve the efficiency of [1-13C]pyruvate polarization via SABRE-SHEATH.

Figure 3.

Figure 3.

a) Stacked variable-temperature SABRE-SHEATH 13C spectra showing the interplay between HP complex 3b and “free” peaks as a function of temperature during hyperpolarization. b) Corresponding stacked plots of HP 13C spectra obtained after SABRE-SHEATH polarization at a fixed temperature of 0 °C, followed by rapid sample warm-up at different temperatures (~25-40 °C), illustrating the step-wise release of HP [1-13C]pyruvate during sample warm-up following hyperpolarization of slow-exchanging complex 3b at the lower temperature. All experiments were performed using the same sample of ~30 mM [1-13C]pyruvate, ~20 mM DMSO, and ~6 mM catalyst in CD3OD. The stacked spectra presented are not to scale.

During the course of our experimental studies, we discovered that our p-H2 generator (98.5% para-)[27] was leaching residual moisture into our samples after repeated p-H2 bubbling (on the time scale of hours), leading to reproducibility challenges. Although this experimental limitation was quickly remedied by thorough drying of the generator by H2 purging at room temperature for 3 days, this observation prompted us to investigate the role of H2O as a potential secondary co-ligand or substrate modifier in SABRE-SHEATH experiments. Indeed, systematic H2O titrations (SI) revealed the dependence of P13C not only on DMSO concentration, but also on water concentration. For example, Figure 4 shows a clear P13C modulation of [1-13C]pyruvate by varying the concentration of H2O added to the sample and variable-temperature SABRE-SHEATH experiments. As a result, the presence of H2O in an optimal concentration (~0.5 M) was found to nearly double P13C (compared to no water added), reaching ~13% at the optimum temperature (~8 °C)—a P13C value that is ~7 times greater than the previously reported P13C value of 1.85%.[16] We speculate that water may potentially act either as a secondary co-ligand, or water molecule may interact with pyruvate and therefore alter [1-13C]pyruvate exchange dynamics of Ir-IMes hexacoordinate complex.

Figure 4.

Figure 4.

a) total 13C polarization of the 13C-1 site (i.e., integrating over all bound and free resonances) in ~30 mM [1-13C]pyruvate in CD3OD (pyruvate to DMSO ratio of 3:2) as a function of H2O concentration and SABRE-SHEATH temperature. See SI for details; b) the 13C NMR spectrum of HP [1-13C]pyruvate with P13C ~ 13% with SABRE-SHEATH at 8 °C and 0.5 M water content.

Although future systematic optimization studies are certainly warranted to further improve 13C polarization efficiency of HP [1-13C]pyruvate produced via SABRE-SHEATH, this report clearly demonstrates that order-unity 13C polarization is fundamentally attainable in this system. Moreover, the P13C value of ~13% demonstrated here for the free substrate (Figure 4) is certainly already useable for in vivo studies[13, 28, 29]; however, future in vivo feasibility studies will need to address remaining translational roadblocks by combining the present polarization techniques with ongoing efforts to achieve rapid SABRE catalyst removal[30-32] and HP [1-13C]pyruvate reconstitution into biocompatible aqueous media of injectable solutions.[29] Furthermore, recent studies utilizing pulsed-SABRE-SHEATH[33] demonstrated that even higher polarization levels may be obtained that using conventional SABRE-SHEATH approach employed here. These so-called pulsed approaches benefit from the coherently driven hyperpolarization dynamics in signal amplification by reversible exchange[34] and more favorable relaxation dynamics of heteronucleus during the pulse performed at tens of microtesla.[23, 26, 35, 36] Indeed, very recent studies demonstrated that heteronuclear polarization can be boosted by a factor of 1.3 when employing pulsed-SABRE-SHEATH, a.k.a., alt-SABRE-SHEATH[37, 38] Therefore, the future SABRE-SHEATH optimization studies of [1-13C]pyruvate may potentially benefit substantially from various pulsed variants. Finally, future robust production of HP [1-13C]pyruvate for biomedical applications (as well as optimization of experimental parameters reported here) using SABRE-SHEATH requires a dedicated purpose-built hyperpolarizer device. All results reported here were obtained using clinical-scale SABRE-SHEATH hyperpolarizer (Figure 1c shows the diagram of the gas manifold and key components within the PHIP hyperpolarizer), the experimental design of which will be described elsewhere similarly to our track record of sharing best laboratory practices of parahydrogen hyperpolarizers’ designs with the scientific community.[39-41]

Conclusions

In conclusion, we have demonstrated that order-unity 13C polarization (P13C>50%) of [1-13C]pyruvate is obtained during SABRE-SHEATH on the catalyst-bound complex 3b—the feasibility of high 13C polarization is also supported by the relaxation dynamics measurements. This is an important proof that highly polarized 13C-carboxylic acids (including key metabolites) can be produced by the SABRE technique. Second, we have shown that temperature modulates the efficiency of SABRE-SHEATH dramatically with optimum temperature of ~8 °C. Third, the presence of water in addition to DMSO co-ligand also modulates SABRE-SHEATH efficiency with the optimum water content found to be ~0.5 M. Taken together the presented results bode well for future biomedical use of [1-13C]pyruvate prepared via SABRE-SHEATH for future biomedical applications.

Supplementary Material

Supporting Information

Acknowledgements

This work was supported by NSF CHE-1905341 and CHE-1904780, NCI 1R21CA220137, NIBIB R21EB025313 and R01EB029829. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. T.T. acknowledges funding from the North Carolina Biotechnology Center and the Mallinckrodt Foundation.

Footnotes

Conflict of Interest

EYC and BMG declare ownership in XeUS Technologies, LTD. Thomas Theis holds stock in Vizma Life Sciences LLC (VLS) and is President of VLS. VLS is developing products related to the research being reported. The terms of this arrangement have been reviewed and approved by NC State University in accordance with its policy on objectivity in research.

References

  • [1].Nikolaou P, Goodson BM, Chekmenev EY, Chem. Eur. J 2015, 21, 3156–3166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].Kovtunov KV, Pokochueva EV, Salnikov OG, Cousin S, Kurzbach D, Vuichoud B, Jannin S, Chekmenev EY, Goodson BM, Barskiy DA, Koptyug IV, Chem. Asian J 2018, 13, 1857–1871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Golman K, Axelsson O, Johannesson H, Mansson S, Olofsson C, Petersson JS, Magn. Reson. Med 2001, 46, 1–5. [DOI] [PubMed] [Google Scholar]
  • [4].Golman K, in't Zandt R, Thaning M, Proc. Natl. Acad. Sci. U. S. A 2006, 103, 11270–11275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ronen S, Tyler DJ, Rajan SS, Spielman DM, Wald L, Zhang X, Malloy CR, Rizi R, Neoplasia 2019, 21, 1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Merritt M, Harrison C, Storey C, Jeffrey F, Sherry A, Malloy C, Proc. Natl. Acad. Sci. U. S. A 2007, 104, 19773–19777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA, Sci. Transl. Med 2013, 5, 198ra108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K, Proc. Natl. Acad. Sci. U. S. A 2003, 100, 10158–10163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Ardenkjaer-Larsen JH, J. Magn. Reson 2016, 264, 3–12. [DOI] [PubMed] [Google Scholar]
  • [10].Bowers CR, Weitekamp DP, Phys. Rev. Lett 1986, 57, 2645–2648. [DOI] [PubMed] [Google Scholar]
  • [11].Reineri F, Boi T, Aime S, Nat. Commun 2015, 6, 5858. [DOI] [PubMed] [Google Scholar]
  • [12].Cavallari E, Carrera C, Aime S, Reineri F, J. Magn. Reson 2018, 289, 12–17. [DOI] [PubMed] [Google Scholar]
  • [13].Cavallari E, Carrera C, Sorge M, Bonne G, Muchir A, Aime S, Reineri F, Sci. Rep 2018, 8, 8366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Adams RW, Aguilar JA, Atkinson KD, Cowley MJ, Elliott PIP, Duckett SB, Green GGR, Khazal IG, Lopez-Serrano J, Williamson DC, Science 2009, 323, 1708–1711. [DOI] [PubMed] [Google Scholar]
  • [15].Kidd B, Mashni J, Limbach M, Shi F, Chekmenev EY, Hou Y, Goodson BM, Chem. Eur. J 2018, 24, 10641–10645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Iali W, Roy SS, Tickner BJ, Ahwal F, Kennerley AJ, Duckett SB, Angew. Chem. Int. Ed 2019, 58, 10271–10275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Tickner BJ, Semenova O, Iali W, Rayner PJ, Whitwood AC, Duckett SB, Catal. Sci. Tech 2020, 10, 1343–1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Gemeinhardt ME, Limbach MN, Gebhardt TR, Eriksson CW, Eriksson SL, Lindale JR, Goodson EA, Warren WS, Chekmenev EY, Goodson BM, Angew. Chem. Int. Ed 2020, 59, 418–423. [DOI] [PubMed] [Google Scholar]
  • [19].Cowley MJ, Adams RW, Atkinson KD, Cockett MCR, Duckett SB, Green GGR, Lohman JAB, Kerssebaum R, Kilgour D, Mewis RE, J. Am. Chem. Soc 2011, 133, 6134–6137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Vazquez-Serrano LD, Owens BT, Buriak JM, Inorg. Chim. Acta 2006, 359, 2786–2797. [Google Scholar]
  • [21].Theis T, Truong ML, Coffey AM, Shchepin RV, Waddell KW, Shi F, Goodson BM, Warren WS, Chekmenev EY, J. Am. Chem. Soc 2015, 137, 1404–1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Barskiy DA, Shchepin RV, Tanner CPN, Colell JFP, Goodson BM, Theis T, Warren WS, Chekmenev EY, ChemPhysChem 2017, 18, 1493–1498. [DOI] [PubMed] [Google Scholar]
  • [23].Truong ML, Theis T, Coffey AM, Shchepin RV, Waddell KW, Shi F, Goodson BM, Warren WS, Chekmenev EY, J. Phys. Chem. C 2015, 119, 8786–8797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Barskiy DA, Kovtunov KV, Koptyug IV, He P, Groome KA, Best QA, Shi F, Goodson BM, Shchepin RV, Coffey AM, Waddell KW, Chekmenev EY, J. Am. Chem. Soc 2014, 136, 3322–3325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Chapman B, Joalland B, Meersman C, Ettedgui J, Swenson RE, Krishna MC, Nikolaou P, Kovtunov KV, Salnikov OG, Koptyug IV, Gemeinhardt ME, Goodson BM, Shchepin RV, Chekmenev EY, Anal. Chem 2021, 93, 8476–8483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Birchall JR, Kabir MSH, Salnikov OG, Chukanov NV, Svyatova A, Kovtunov KV, Koptyug IV, Gelovani JG, Goodson BM, Pham W, Chekmenev EY, Chem. Comm 2020, 56, 9098–9101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Nantogma S, Joalland B, Wilkens K, Chekmenev EY Anal. Chem 2021, 93, 3594–3601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM, Nat. Med 2007, 13, 1382–1387. [DOI] [PubMed] [Google Scholar]
  • [29].Hövener J-B, Pravdivtsev AN, Kidd B, Bowers CR, Glöggler S, Kovtunov KV, Plaumann M, Katz-Brull R, Buckenmaier K, Jerschow A, Reineri F, Theis T, Shchepin RV, Wagner S, Bhattacharya P, Zacharias NM, Chekmenev EY, Angew. Chem. Int. Ed 2018, 57, 11140–11162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Kidd BE, Gesiorski JL, Gemeinhardt ME, Shchepin RV, Kovtunov KV, Koptyug IV, Chekmenev EY, Goodson BM, J. Phys. Chem. C 2018, 122, 16848–16852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Barskiy DA, Ke LA, Li X, Stevenson V, Widarman N, Zhang H, Truxal A, Pines A, J. Phys. Chem. Lett 2018, 9, 2721–2724. [DOI] [PubMed] [Google Scholar]
  • [32].Mewis RE, Fekete M, Green GGR, Whitwood AC, Duckett SB, Chem. Comm 2015, 51, 9857–9859. [DOI] [PubMed] [Google Scholar]
  • [33].Tanner CPN, Lindale JR, Eriksson SL, Zhou Z, Colell JFP, Theis T, Warren WS, J. Chem. Phys 2019, 151, 044201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Lindale JR, Eriksson SL, Tanner CPN, Zhou Z, Colell JFP, Zhang G, Bae J, Chekmenev EY, Theis T, Warren WS, Nat. Commun 2019, 10, 395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].Shchepin RV, Jaigirdar L, Chekmenev EY, J. Phys. Chem. C 2018, 122, 4984–4996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Salnikov OG, Chukanov NV, Svyatova A, Trofimov IA, Kabir MSH, Gelovani JG, Kovtunov KV, Koptyug IV, Chekmenev EY, Angew. Chem. Int. Ed 2021, 60, 2406–2413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Eriksson SL, Lindale JR, Li X, Warren WS, arXiv 2021, arXiv:2107.04687. [Google Scholar]
  • [38].Pravdivtsev AN, Kempf N, Plaumann M, Bernarding J, Scheffler K, Hövener J-B, Buckenmaier K, ChemPhysChem 2021, 10.1002/cphc.202100543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].TomHon PM, Han S, Lehmkuhl S, Appelt S, Chekmenev EY, Abolhasani M, Theis T, ChemPhysChem 2021, 10.1002/cphc.202100667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Coffey AM, Shchepin RV, Truong ML, Wilkens K, Pham W, Chekmenev EY, Anal. Chem 2016, 88, 8279–8288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Coffey AM, Shchepin RV, Feng B, Colon RD, Wilkens K, Waddell KW, Chekmenev EY, J. Magn. Reson 2017, 284, 115–124. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

RESOURCES